Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., . . . Slamon, D. J. (2023). Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Research, 25(1), 1-11.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Neven, P., et al. "Updated Overall Survival from the MONALEESA-3 Trial in Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Receiving First-line Ribociclib Plus Fulvestrant."
Breast Cancer Research 25, no. 1 (2023): 1-11.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Neven, P., et al. "Updated Overall Survival from the MONALEESA-3 Trial in Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Receiving First-line Ribociclib Plus Fulvestrant."
Breast Cancer Research, vol. 25, no. 1, 2023, pp. 1-11.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.